Leonard W. Seymour
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Leonard W. Seymour | |
|---|---|
| Born | 1958 Plymouth, England, UK |
| Alma mater | University of Manchester |
| Known for | Oncolytic Virotherapy |
| Scientific career | |
| Fields | Gene Therapy |
| Institutions | University of Birmingham University of Oxford |
Leonard W. Seymour is a Professor of Gene Therapy at the University of Oxford's oncology department.[1] As a cancer-oriented translational researcher, he investigates technologies utilised to enhance targeted therapy's (e.g. drugs, genes, oncolytic virus) delivery and develops related biological therapeutics under the support of Cancer Research UK.[2]
Life[edit]
Professor Seymour was born in Plymouth, United Kingdom, in 1958. He read Biochemistry at the University of Manchester.[3] He later formed a research group focused on gene delivery at the Cancer Research UK Institute in Birmingham, and then relocated to the University of Oxford in 2003 as Gene Therapy lead for the National Translational Cancer Research Network (NTRAC). There, he took part in forming the British Society for Gene Therapy (BSCGT) as a means to build the translational gene and cell therapy community within the UK.[4]
Seymour served as the first President of the BSGCT from 2003 to 2009,[5] currently serves as the General Secretary of the European Society for Gene and Cell Therapy,[6] is indexed in Who's Who,[7] and has produced approximately 140 primary scientific publications.
With Dr. Kerry Fisher, Prof. Seymour formed a biotech spinout company 'Hybrid Systems'[8] which later became ‘PsiOxus Therapeutics Ltd’, with Cancer Research UK and the University of Birmingham. PsiOxus is now developing a cancer-killing 'oncolytic' group B adenovirus 'ColoAd1' in a series of clinical trials to treat cancer. More recently with Dr. Ryan Cawood, Dr. Seymour formed the plasmid expression company OxGENE,[9] aiming to enable major improvements in the efficiency of genetic engineering and synthetic biology. In 2021, OxGENE was sold to WuXi AppTec.[10]
His brother Paul Seymour is a professor of mathematics at Princeton University.
References[edit]
- ^ "Len Seymour". www.oncology.ox.ac.uk. Retrieved 3 July 2022.
- ^ "How we spend your money". cancerresearchuk.org. 8 June 2016.
- ^ "LinkedIn Profile". LinkedIn. Retrieved 3 July 2022.
- ^ Seymour LW; Steering Executive Committee of the British Society for Gene Therapy, Trial and error, Lancet, 2003;361(9368):1568.
- ^ "Len Seymour: This is only the beginning of what gene therapy can do". independent.co.uk. 28 April 2008.
- ^ "Board Members". www.esgct.eu.
- ^ "Seymour, Prof. Leonard William, (born 4 Sept. 1958), Professor of Gene Therapies, University of Oxford, since 2002 (Head, Department of Clinical Pharmacology, 2009–10) - WHO'S WHO & WHO WAS WHO". ukwhoswho.com.
- ^ "Interview" (PDF). beremans.com.
- ^ "Home". oxgene.com. Retrieved 3 July 2022.
- ^ "Oxford Genetics (Oxgene) sells to international life sciences group - Business & Innovation Magazine". 2 March 2021. Retrieved 3 July 2022.